An oral protein cocktail therapeutic for C. difficile infection

LMN-201, a spirulina-delivered four-component monoclonal protein cocktail for Clostridioides difficile infection, achieved 100% initial clinical cure (21/21) and 90.5% sustained cure through four weeks (19/21).

• Why it matters: Effective oral biologics for GI infections are hard to scale and engineer, and monoclonal protein therapies often struggle with potency and delivery to intestinal sites.
• What they did: Antibody-like moieties were designed with a synthetic avidity framework to boost in vitro toxin neutralization potency by >200-fold, and a lysin moiety added toxinotype-agnostic antibacterial activity; rodent challenge models and a human GI pharmacokinetic study supported distal-intestine exposure.
• The result: In Part A of a Phase 2 study, seven days of LMN-201 plus standard-of-care antibiotics showed favorable safety/tolerability and interim efficacy consistent with high cure rates, supporting spirulina as a scalable oral biologics platform.

AI summary of the abstract · may contain errors · not medical advice · read the paper.